=> File .Biotech => s (polypeptide# or peptide# or therapeut? peptide or polypeptide) 1697755 (POLYPEPTIDE# OR PEPTIDE# OR THERAPEUT? PEPTIDE OR POLYPEPTIDE) => s 11 and (glutamic acid or aspartic acid or alanine or asparagine or glutamine or glycine) 6 FILES SEARCHED... 166239 L1 AND (GLUTAMIC ACID OR ASPARTIC ACID OR ALANINE OR ASPARAGINE OR GLUTAMINE OR GLYCINE) => s 12 and (drug cariier) 0 L2 AND (DRUG CARIIER) => s 12 and (drug carier) 0 L2 AND (DRUG CARIER) L4=> s 12 and (carrier) 39614 L2 AND (CARRIER) => s 15 and (drug) 24549 L5 AND (DRUG) Ь6 => s 16 and (metal complex?) 2071 L6 AND (METAL COMPLEX?) Ь7 => s 17 and (conjugat? or combin? or join? or link? (5a)covalent?) 2070 L7 AND (CONJUGAT? OR COMBIN? OR JOIN? OR LINK? (5A) COVALENT?) => s 18 and (metal drug) L9 7 L8 AND (METAL DRUG) => d 19 1-7 bib ab ANSWER 1 OF 7 USPATFULL on STN L9 2003:176406 USPATFULL ANPharmaceutical preparations of glutathione and methods of administration TI Demopolos, Harry B., Scarsdale, NY, United States TN Seligman, Myron L., Pleasantville, NY, United States Antioxidant Pharmaceuticals Corp., Elsmsford, NY, United States (U.S. PA corporation) 20030701 US 6586404 B1 PT ΑT US 2002-200852 20020722 (10) Continuation of Ser. No. US 2001-813247, filed on 19 Mar 2001, now RLI patented, Pat. No. US 6423687 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now patented, Pat. No. US 6159500 Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US 6204248 PRAI US 1996-34101P 19961231 (60) DT Utility FS GRANTED Primary Examiner: Reamer, James H. EXNAM Milde & Hoffberg LLP LREP CLMN Number of Claims: 33 ECL Exemplary Claim: 1,20 DRWN 2 Drawing Figure(s); 2 Drawing Page(s) LN.CNT 3836 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A method for the administration of glutathione orally comprising the ΑB administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

```
2003:159817 USPATFULL
AN
ΤI
       Anticancer polypeptide-metal complexes and
       compositions, methods of making, and methods of using same
       Zuo, William W., Sugar Land, TX, UNITED STATES
TN
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES
       Xu, Jing Ya, Missouri City, TX, UNITED STATES
       US 2003109432
                          A1
                               20030612
PT
                               20011210 (9)
ΑI
       US 2001-940180
                          A1
DT
       Utility
FS
       APPLICATION
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
LREP
       Bellaire, TX, 77402-2428
       Number of Claims: 54
CLMN
       Exemplary Claim: 1
ECL
DRWN
       10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel drug complexes comprising a polypeptide
AB
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
       , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
       The drug moiety is a therapeutic metal selected from the group
       consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt,
       indium, gallium or rhodium. Methods for making said complexes,
       compositions comprising said complexes, methods for making saiduch
       compositions, and methods for treating a patient comprising use of said
       complexes and/or compositions are further disclosed.
     ANSWER 3 OF 7 USPATFULL on STN
Ь9
       2002:250825 USPATFULL
AN
       Pharmaceutical preparations of glutathione and methods of administration
TT
       Demopoulos, Harry B., Scarsdale, NY, UNITED STATES
IN
       Seligman, Myron L., Pleasantville, NY, UNITED STATES
                          A1
                               20020926
PΙ
       US 2002136763
ΑI
       US 2002-83327
                          Α1
                               20020225 (10)
       A 371 of International Ser. No. WO 1997-US23879, filed on 31 Dec 1997,
RLI
       UNKNOWN Continuation-in-part of Ser. No. US 1999-331947, filed on 28 Jun
       1999, GRANTED, Pat. No. US 6350467
                           19961231 (60)
       US 1996-34101P
PRAI
       Utility
DT
       APPLICATION
FS
       Steven M. Hoffberg, MILDE & HOFFBERG, LLP, SUITE 460, 10 BANK STREET,
LREP
       WHITE PLAINS, NY, 10606
CLMN
       Number of Claims: 59
       Exemplary Claim: 1
ECL
       2 Drawing Page(s)
DRWN
LN.CNT 2416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method of increasing glutathione levels in mammalian cells comprising
AB
       administering an oral bolus of encapsulated pharmaceutically stabilized
       glutathione in a rapidly dissolving formulation to a mammal on an empty
       stomach. Pharmaceutical formulations including glutathione are also
       disclosed.
T<sub>1</sub>9
     ANSWER 4 OF 7 USPATFULL on STN
       2002:181670 USPATFULL
AN
       Pharmaceutical preparations of glutathione and methods of administration
TI
       Demopolos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Pleasantville, NY, United States
PA
       Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
```

corporation)

```
US 6423687
РΤ
                                20020723
       US 2001-813247
                                20010319 (9)
AI
       Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now
RLT
       patented, Pat. No. US 6204248 Continuation of Ser. No. US 1997-2100,
       filed on 31 Dec 1997, now patented, Pat. No. US 6159500
       US 1996-34101P
                           19961231 (60)
PRAI
DT
       Utility
       GRANTED
FS
EXNAM
       Primary Examiner: Reamer, James H.
       Milde & Hoffberg, LLP
CLMN
       Number of Claims: 20
       Exemplary Claim: 1
ECL
DRWN
       2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method for the administration of glutathione orally comprising the
AB
       administration of a bolus of glutathione which is pharmaceutically
       stabilized and encapsulated. The glutathione is administered on an empty
       stomach. The preferred stabilizer is ascorbic acid.
    ANSWER 5 OF 7 USPATFULL on STN 2002:39674 USPATFULL
L9
ΑN
       Pharmaceutical preparations of glutathione and methods of administration
TI
       Demopoulos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Pleasantville, NY, United States
       Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
PA
       corporation)
рT
       US 6350467
                          B1
                                20020226
       WO 9829101 19980709
       US 1999-331947
                                19990628 (9)
ΑТ
       WO 1997-US23879
                                19971231
                                19990628 PCT 371 date
PRAI
       US 1996-34101P
                           19961231 (60)
       Utility
DТ
       GRANTED
       Primary Examiner: Spear, James M.
       Milde, Hoffberg & Macklin, LLP
LREP
CLMN
       Number of Claims: 62
       Exemplary Claim: 1
ECL
       2 Drawing Figure(s); 2 Drawing Page(s)
DRWN
LN.CNT 2366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method of increasing glutathione levels in mammalian cells comprising
AB
       administering an oral bolus of encapsulated pharmaceutically stabilized
       glutathione in a rapidly dissolving formulation to a mammal on an empty
       stomach. Pharmaceutical formulations including glutathione are also
       disclosed.
L9
     ANSWER 6 OF 7 USPATFULL on STN
       2001:40462 USPATFULL
ΑN
       Pharmaceutical preparations of glutathione and methods of administration
ΤI
       Demopoulos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Fairfield, CT, United States
       Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
       corporation)
       US 6204248
                          В1
                               20010320
PΤ
       US 1999-457642
                               19991209 (9)
AΙ
       Continuation of Ser. No. US 331947 Continuation of Ser. No. US
RLI
       1997-2100, filed on 31 Dec 1997, now abandoned
       US 1996-34101P
                          19961231 (60)
PRAI
       Utility
DT
       Primary Examiner: Reamer, James H.
EXNAM
```

```
Milde, Hoffberg & Macklin, LLP
LREP
CLMN
       Number of Claims: 14
ECL
       Exemplary Claim: 1
DRWN
       2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 5144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method of altering an expression of a gene product in cells or an
       organism, comprising orally administering glutathione in an effective
       amount and under such conditions to alter a redox potential in the
       cells. The gene expression may be sensitive to redox potential through
       one or more of a process of induction, transcription, translation,
       post-translational modification, release, and/or through a receptor
       mediated process. The glutathione is preferably administered as an oral
       bolus of encapsulated pharmaceutically stabilized glutathione in a
       rapidly dissolving formulation to a mammal on an empty stomach.
L9
     ANSWER 7 OF 7 USPATFULL on STN
       2000:167548 USPATFULL
AN
       Pharmaceutical preparations of glutathione and methods of administration
TI
       thereof
       Demopoulos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Pleasantville, NY, United States
PA
       Antioxidant Pharmaceuticals Corporation, Elmsford, NY, United States
       (U.S. corporation)
PТ
       US 6159500
                               20001212
       US 1997-2100
ΑI
                               19971231 (9)
DT
       Utility
FS
       Granted
EXNAM
      Primary Examiner: Spear, James M.
       Milde, Hoffberg & Macklin, LLP
LREP
CLMN
       Number of Claims: 59
       Exemplary Claim: 1
ECL
       2 Drawing Figure(s); 2 Drawing Page(s)
DRWN
LN.CNT 2389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method for the administration of glutathione orally comprising the
       administration of a bolus of glutathione which is pharmaceutically
       stabilized and encapsulated. The glutathione is administered on an empty
       stomach. The preferred stabilizer is ascorbic acid.
=> s 18 and (transition? metal drug)
             1 L8 AND (TRANSITION? METAL DRUG)
=> d l10 bib ab
L10 ANSWER 1 OF 1 USPATFULL on STN
ΑN
       2003:159817 USPATFULL
       Anticancer polypeptide-metal complexes and
TI
       compositions, methods of making, and methods of using same
       Zuo, William W., Sugar Land, TX, UNITED STATES
IN
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES
       Xu, Jing Ya, Missouri City, TX, UNITED STATES
                       A1
ΡI
       US 2003109432
                               20030612
ΑI
       US 2001-940180
                          A1
                               20011210 (9)
DT
       Utility
FS
       APPLICATION
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
LREP
       Bellaire, TX, 77402-2428
       Number of Claims: 54
CLMN
       Exemplary Claim: 1
ECL
DRWN
       10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
AΒ
       Novel drug complexes comprising a polypeptide
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
       , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
       The drug moiety is a therapeutic metal selected from the group
       consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt,
       indium, gallium or rhodium. Methods for making said complexes,
       compositions comprising said complexes, methods for making saiduch
       compositions, and methods for treating a patient comprising use of said
       complexes and/or compositions are further disclosed.
=> s 18 and (metal complex?)
          2070 L8 AND (METAL COMPLEX?)
=> s 111 and (platinum or iron or gadolinium or rhenium or manganese or cobolt or
indium or gallium or rhodium)
           647 L11 AND (PLATINUM OR IRON OR GADOLINIUM OR RHENIUM OR MANGANESE
               OR COBOLT OR INDIUM OR GALLIUM OR RHODIUM)
=> s 112 and (therapeutic metal)
             8 L12 AND (THERAPEUTIC METAL)
=> d 113 1-8 bib ab
L13 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
     2003:173371 CAPLUS
AN
DN
     138:226718
     Compositions containing anticancer polypeptide-metal
TI
     complexes
     Zuo, William W.; Xu, Jing Ya
IN
PA
     Fannin Bioscience, Inc., USA
SO
     PCT Int. Appl., 78 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LΑ
FAN.CNT 1
                                            APPLICATION NO. DATE
     PATENT NO.
                     KIND DATE
                                             _____
         2003017923 A2 20030306 WO 2002-US21624 20020709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
     WO 2003017923
PI
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             US 2001-940180
     US 2003109432
                             20030612
                                                               20011210
                       A1
PRAI US 2001-940180
                       Α
                             20011210
     Novel drug complexes comprising a polypeptide
     carrier moiety comprising glutamic acid and at
     least one of the group consisting of aspartic acid,
     alanine, asparagine, glutamine,
     glycine, and any combinations thereof, are disclosed.
     The drug moiety is a therapeutic metal
     selected from the group consisting of platinum, iron,
     gadolinium, rhenium, manganese, cobalt,
     indium, gallium or rhodium. Methods for
     making the complexes, compns. comprising the complexes, methods for making
     such compns., and methods for treating a patient with these complexes are
     also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by
     the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate.
```

```
Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated
     with the poly(amino acid) prepd. above to give a complex.
     was evaluated in 4 tumor-bearing animal models. The platinum
     peptide complexes are all effective in vivo against breast cancer.
    ANSWER 2 OF 8 USPATFULL on STN
       2003:159817 USPATFULL
       Anticancer polypeptide-metal complexes and
       compositions, methods of making, and methods of using same
       Zuo, William W., Sugar Land, TX, UNITED STATES
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES
       Xu, Jing Ya, Missouri City, TX, UNITED STATES
       US 2003109432
                          A1
                                20030612
       US 2001-940180
                          A1
                                20011210 (9)
       Utility
       APPLICATION
LREP
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
       Bellaire, TX, 77402-2428
CLMN
       Number of Claims: 54
       Exemplary Claim: 1
DRWN
       10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel drug complexes comprising a polypeptide
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
        alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
       The drug moiety is a therapeutic metal
       selected from the group consisting of platinum, iron
         gadolinium, rhenium, manganese, cobalt,
       indium, gallium or rhodium. Methods for
       making said complexes, compositions comprising said complexes, methods
       for making saiduch compositions, and methods for treating a patient
       comprising use of said complexes and/or compositions are further
       disclosed.
L13 ANSWER 3 OF 8 USPATFULL on STN
       2001:231038 USPATFULL
       Structurally determined cyclic metallo-constructs and applications
       Sharma, Shubh D., Plainsboro, NJ, United States
       Palatin Technologies, Inc., Princeton, NJ, United States (U.S.
       corporation)
       US 6331285
                                20011218
       US 1999-464358
                                19991215 (9)
       Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented,
       Pat. No. US 6027711
       Utility
       GRANTED
       Primary Examiner: Jones, Dameron L.
EXNAM
       Slusher, Stephen A. Peacock, Myers & Adams
LREP
       Number of Claims: 16
CLMN
       Exemplary Claim: 1
DRWN
       20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or
       radiotherapeutic agent, and for use in library or combinatorial
       chemistry methods. The construct has a conformationally constrained
       qlobal secondary structure obtained upon complexing with a metal ion.
       The peptide constructs are of the general formula:
```

AN TT

IN

PΙ

ΑI

DT

FS

ECL

NATI

IN

PA

ΡI

AΙ

DT

FS

RLI

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

```
L13 ANSWER 4 OF 8 USPATFULL on STN
       2000:109372 USPATFULL
ΑN
       In vivo agents comprising cationic drugs, peptides and metal
TT
       chelators with acidic saccharides and glycosaminoglycans, giving
       improved site-selective localization, uptake mechanism, sensitivity and
       kinetic-spatial profiles, including tumor sites
Ranney, David F., Dallas, TX, United States
Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S.
IN
PΑ
       corporation)
       US 6106866
                                20000822
PΤ
       US 1995-509338
                                19950731 (8)
ΑI
DT
       Utility
FS
       Granted
      Primary Examiner: Woodward, Michael P.
EXNAM
       Arnold, White & Durkee
LREP
CLMN
       Number of Claims: 23
ECL
       Exemplary Claim: 1
       21 Drawing Figure(s); 72 Drawing Page(s)
DRWN
LN.CNT 3913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A drug carrier composition comprising a drug
       complexed with dermatan sulfate is disclosed. The drug is
       preferably an anti tumor drug and may be taxol, a
       peptide onco-agent or vincristine. The most preferred antitumor
       drug is doxorubicin. The dermatan sulfate is essentially
       purified dermatan sulfate with a sulfur content of up to 9% (w/w) and
       with selective oligosaccharide oversulfation. The compositions are
       administered in a fashion that allows efficient vascular access and
       induces the following in vivo effects: 1) rapid, partial or total
       endothelial envelopment of the drug (diagnostic)
       carrier; 2) sequestration of the carrier and
       protection of the entrapped agent from blood vascular clearance at an
       early time (2 minutes) when the endothelial pocket which envelops the
       carrier still invaginates into the vascular compartment; 3)
       acceleration of the carrier's transport across and/or through
       the vascular endothelium or subendothelial structures into the tissue
       compartment (interstitium); and 4) improvement of the efficiency with
       which the drug migrates across the endothelium, or
       epi-endothelial or subendothelial barriers, such that a lower total
       drug dose is required to obtain the desired effect relative to
       that required for standard agents. Analogous tissue uptake is described
       for transepithelial migration into the lungs, bladder and bowel.
L13 ANSWER 5 OF 8 USPATFULL on STN
       2000:21206 USPATFULL
AN
       Structurally determined metallo-constructs and applications
TI
       Sharma, Shubh D., Albuquerque, NM, United States
IN
PΑ
       RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)
```

20000222

19960605 (8)

US 6027711

US 1996~660697

PΤ

ДΤ

Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999 DТ Utility FS Granted Primary Examiner: Dees, Jose G.; Assistant Examiner: Jones, Dameron EXNAM Slusher, Stephen A., Todaro, John C., Peacock, Deborah A. Number of Claims: 38 CLMN ECL Exemplary Claim: 1 20 Drawing Figure(s); 14 Drawing Page(s) LN.CNT 4915 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or **combinatorial** chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L13 ANSWER 6 OF 8 USPATFULL on STN 1998:138472 USPATFULL ANTIDendrimeric compounds Margerum, Larry, Wayne, PA, United States IN Campion, Brian, Solano Beach, CA, United States Fellmann, Jere Douglas, Livermore, CA, United States Garrity, Martha, San Clemente, CA, United States Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation) PA19981110 PΙ US 5834020 WO 9528966 19951102 US 1997-722082 19970121 (8) ΑI WO 1995-GB898 19950420 19970121 PCT 371 date 19970121 PCT 102(e) date PRAI GB 1994-7812 19940420 DTUtility FS Granted EXNAM Primary Examiner: Levy, Neil S. Fish & Richardson P.C. LREP CLMN Number of Claims: 17 ECL Exemplary Claim: 1 DRWN No Drawings LN.CNT 2049 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

L13 ANSWER 7 OF 8 USPATFULL on STN 93:93543 USPATFULL Methods and compositions for magnetic resonance imaging comprising TI superparamagnetic ferromagnetically coupled chromium complexes Ranney, David F., 3539 Courtdale Dr., Dallas, TX, United States 75234 IN ΡI US 5260050 19931109 US 1990-463692 19900111 (7) ΑI 20100525 DCD Continuation-in-part of Ser. No. US 1988-252565, filed on 29 Sep 1988, RLI now abandoned DT Utility Granted FS Primary Examiner: Hollrah, Glennon H.; Assistant Examiner: Hollinden, EXNAM Gary E. LREP Arnold, White Durkee Number of Claims: 29 CLMN Exemplary Claim: 1 ECL 8 Drawing Figure(s); 12 Drawing Page(s) CAS INDEXING IS AVAILABLE FOR THIS PATENT. Improved compositions and methods for selective access to tumor regions AΒ (or other regions of abnormal endothelial properties). This capability provides powerful contrast-enhancement agents for nuclear magnetic resonance imaging. A polyatomic complex which includes intramolecular ferromagnetic coupling between metal atoms is associated with a polymer or microsphere carrier matrix which will bind to endothelial determinants. A solution containing this carrier complex is injected into a human (or other) body to be imaged. The carrier complex will preferentially extravasate at locations where the blood vessel walls have increased porosity or microvascular surface changes, and especially at tumor sites. Thus, the changes in relaxation time induced by the presence of the carrier complex will provide a high-gain marker for magnetic resonance imaging. Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core. L13 ANSWER 8 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN 2003-363003 [34] WPIDS ΑN DNC C2003-095754 TIGlutamic acid containing polypeptidemetal complexes, useful for treating patients afflicted with conditions e.g. cancer. DC B04 B05 XU, JY; YANG, DJ; YU, D; ZUO, WW IN(XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; PA (FANN-N) FANNIN BIOSCIENCE INC CYC PΙ WO 2003017923 A2 20030306 (200334)* EN 78p RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW US 2003109432 A1 20030612 (200340) WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 ADT 20010827 PRAI US 2001-940180 20010827 WO2003017923 A UPAB: 20030529 NOVELTY - A therapeutic compound comprises at least one drug moiety covalently linked to at least one polypeptide drug carrier moiety (comprising 50 to 90% glutamic acid and 10 to 50% of aspartic

```
and/or glycine).
          DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
          (1) a method for making the therapeutic compound;
          (2) compositions comprising the therapeutic compound;
          (3) a method for making the composition;
          (4) a method for treating a patient comprising administration of the
     compound.
          ACTIVITY - Cytostatic.
          Cis-1,2-diaminocyclohexane platinum(II)-poly(glutamic/
     aspartic acid) (Ia) at 45 mg/kg reduced a breast tumor
     volume from 4000 mm3 to zero over 6 days. A control treated with saline
     showed tumor growth over 6 days to 16000 mm3.
          MECHANISM OF ACTION - None given.
          USE - The compounds are useful for treating patients afflicted with a
     condition (claimed) especially cancer (prostate, breast, ovarian, colonic,
     leukemia, lymphoma, sarcoma, head and neck, lung or liver).
          ADVANTAGE - The compounds have improved solubility of the therapeutic
     agent.
    Dwg.0/7
=> s 112 and (polypeptide platnium complex)
             O L12 AND (POLYPEPTIDE PLATNIUM COMPLEX)
=> s 112 and (platnium complex?)
             O L12 AND (PLATNIUM COMPLEX?)
=> s l12 and (platnium)
             O L12 AND (PLATNIUM)
L16
=> s 112 and (polyglutamate asparatate or polyglutamate alanine)
             O L12 AND (POLYGLUTAMATE ASPARATATE OR POLYGLUTAMATE ALANINE)
L17
=> s 112 and (diaminocyclohexane platinum II or diaminocyclohexane dichloro
platinum IV)
             2 L12 AND (DIAMINOCYCLOHEXANE PLATINUM II OR DIAMINOCYCLOHEXANE
L18
               DICHLORO PLATINUM IV)
=> d l18 1-2 bib ab
L18 ANSWER 1 OF 2 USPATFULL on STN
       2003:159817 USPATFULL
MΤ
ΤI
       Anticancer polypeptide-metal complexes and
       compositions, methods of making, and methods of using same
       Zuo, William W., Sugar Land, TX, UNITED STATES
IN
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES
       Xu, Jing Ya, Missouri City, TX, UNITED STATES
PΙ
       US 2003109432
                          A1
                               20030612
       US 2001-940180
                               20011210 (9)
AΙ
                          A1
DT
       Utility
FS
       APPLICATION
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
       Bellaire, TX, 77402-2428
       Number of Claims: 54
CLMN
ECL
       Exemplary Claim: 1
       10 Drawing Page(s)
DRWN
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel drug complexes comprising a polypeptide
AB
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
       , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
```

acid, alanine, asparagine, glutamine

consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium or rhodium. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed. ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN L182003-363003 [34] WPIDS DNC C2003-095754 Glutamic acid containing polypeptidemetal complexes, useful for treating patients afflicted with conditions e.g. cancer. B04 B05 XU, J Y; YANG, D J; YU, D; ZUO, W W (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; (FANN-N) FANNIN BIOSCIENCE INC CYC WO 2003017923 A2 20030306 (200334)* EN 78p RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW US 2003109432 A1 20030612 (200340) ADT WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 20010827 PRAI US 2001-940180 20010827 WO2003017923 A UPAB: 20030529 NOVELTY - A therapeutic compound comprises at least one drug moiety covalently linked to at least one polypeptide drug carrier moiety (comprising 50 to 90% glutamic acid and 10 to 50% of aspartic acid, alanine, asparagine, glutamine and/or glycine). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a method for making the therapeutic compound; (2) compositions comprising the therapeutic compound; (3) a method for making the composition; (4) a method for treating a patient comprising administration of the compound. ACTIVITY - Cytostatic. Cis-1,2-diaminocyclohexane platinum(II)-poly(glutamic/aspartic acid) (Ia) at 45 mg/kg reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control treated with saline showed tumor growth over 6 days to 16000 mm3. MECHANISM OF ACTION - None given. USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic, leukemia, lymphoma, sarcoma, head and neck, lung or liver). ADVANTAGE - The compounds have improved solubility of the therapeutic agent. Dwg.0/7 => s 112 and (platinum complex?) 9 L12 AND (PLATINUM COMPLEX?) => d 119 1-9 b ib ab 'B' IS NOT A VALID FORMAT 'IB' IS NOT A VALID FORMAT In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages

The drug moiety is a therapeutic metal selected from the group

AN

тT

DC

IN

PA

PI

```
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):d 119 1-9 bib ab
'D' IS NOT A VALID FORMAT
'L152' IS NOT A VALID FORMAT
'1-9' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT): bib ab
     ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
L19
AN
     2003:173371 CAPLUS
DN
     138:226718
     Compositions containing anticancer polypeptide-metal
TI
     complexes
     Zuo, William W.; Xu, Jing Ya
IN
PA
     Fannin Bioscience, Inc., USA
     PCT Int. Appl., 78 pp.
SO
     CODEN: PIXXD2
DT
     Patent
T.A
     English
FAN.CNT 1
                                               APPLICATION NO. DATE
                       KIND DATE
     PATENT NO.
                       _ _ _ _
                              ------
                               20030306
                                               WO 2002-US21624 20020709
     WO 2003017923
                       A2
PТ
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
              RO, RU, SD
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
              PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
              NE, SN, TD, TG
     US 2003109432
                         A1
                               20030612
                                               US 2001-940180
                                                                  20011210
PRAI US 2001-940180
                         Α
                               20011210
     Novel drug complexes comprising a polypeptide
     carrier moiety comprising glutamic acid and at
     least one of the group consisting of aspartic acid,
     alanine, asparagine, glutamine,
     glycine, and any combinations thereof, are disclosed.
     The drug moiety is a therapeutic metal selected from the group
     consisting of platinum, iron, gadolinium,
     rhenium, manganese, cobalt, indium,
     gallium or rhodium. Methods for making the complexes,
     compns. comprising the complexes, methods for making such compns., and
     methods for treating a patient with these complexes are also disclosed.
     Thus, polyaspartate-polyglutamate complex was prepd. by the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate.
     Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated
     with the poly(amino acid) prepd. above to give a complex.
                                                                      This complex
     was evaluated in 4 tumor-bearing animal models. The platinum
     peptide complexes are all effective in vivo against breast cancer.
     ANSWER 2 OF 9 USPATFULL on STN
L19
        2003:203373 USPATFULL
NΑ
        Electronic methods for the detection of analytes utilizing monolayers
ΤI
       Yu, Changjun, Pasadena, CA, United States
Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S.
TN
PA
       corporation)
       US 6600026
                                  20030729
PΙ
                            В1
ΑI
       US 1999-306653
                                  19990506 (9)
       Continuation of Ser. No. US 1998-135183, filed on 17 Aug 1998
RLI
```

or the STNGUIDE file for information on formats available in

```
PRAI
       US 1998-84652P
                            19980506 (60)
       US 1998-84509P
                            19980506 (60)
DT
       Utility
FS
       GRANTED
EXNAM
       Primary Examiner: Riley, Jezia
       Silva, Robin M., Kosslak, Renee M., Dorsey & Whitney, LLP
CLMN
       Number of Claims: 12
       Exemplary Claim: 1
ECL
DRWN
       93 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 4573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The present invention relates to the use of self-assembled monolayers
AΒ
       with mixtures of conductive oligomers and insulators to detect target
       analytes.
L19 ANSWER 3 OF 9 USPATFULL on STN
       2003:159817 USPATFULL
MA
TI
       Anticancer polypeptide-metal complexes and
       compositions, methods of making, and methods of using same
TN
       Zuo, William W., Sugar Land, TX, UNITED STATES
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES Xu, Jing Ya, Missouri City, TX, UNITED STATES
PΙ
       US 2003109432
                           Α1
                                20030612
       US 2001-940180
ΑI
                                20011210 (9)
                           A1
DТ
       Utility
FS
       APPLICATION
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
LREP
       Bellaire, TX, 77402-2428
       Number of Claims: 54
CLMN
ECL
       Exemplary Claim: 1
       10 Drawing Page(s)
DRWN
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel drug complexes comprising a polypeptide
AB
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
       , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
       The drug moiety is a therapeutic metal selected from the group
       consisting of platinum, iron, gadolinium,
       rhenium, manganese, cobalt, indium,
       gallium or rhodium. Methods for making said complexes,
       compositions comprising said complexes, methods for making saiduch
       compositions, and methods for treating a patient comprising use of said
       complexes and/or compositions are further disclosed.
L19 ANSWER 4 OF 9 USPATFULL on STN
AN
       2002:322479 USPATFULL
       Methods of high-throughput screening for internalizing antibodies
TI
       Marks, James D., Kensington, CA, UNITED STATES
IN
       Nielsen, Ulrik B., Brookline, MA, UNITED STATES
       Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
ΡI
       US 2002182643
                          A1
                                20021205
ΑI
       US 2001-981636
                           Α1
                                20011016 (9)
       US 2000-241279P
                           20001018 (60)
PRAI
DT
       Utility
FS
       APPLICATION
       QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
LREP
       94501
       Number of Claims: 72
CLMN
ECL
       Exemplary Claim: 1
DRWN
       8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AΒ This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized. ANSWER 5 OF 9 USPATFULL on STN AN 2001:157679 USPATFULL TISystems for electrophoretic transport and detection of analytes IN Kayyem, Jon Faiz, Pasadena, CA, United States Blackburn, Gary, Glendora, CA, United States O'Connor, Stephen D., Pasadena, CA, United States PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation) PΙ US 6290839 20010918 ΑI US 1998-134058 19980814 (9) US 1998-90389P PRAI 19980623 (60) DT Utility FS GRANTED EXNAM Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex Flehr Hohbach Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., LREP Silva, Esq., Robin M. CLMN Number of Claims: 28 ECL Exemplary Claim: 1 DRWN 44 Drawing Figure(s); 21 Drawing Page(s) LN.CNT 4594 CAS INDEXING IS AVAILABLE FOR THIS PATENT. The invention relates to compositions and methods useful in the electrophoretic transport of target analytes to a detection electrode comprising a self-assembled monolayer (SAM). Detection proceeds through the use of an electron transfer molety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM. ANSWER 6 OF 9 USPATFULL on STN 2001:116434 USPATFULL L19 NATI Binding acceleration techniques for the detection of analytes Blackburn, Gary, Glendora, CA, United States INCreager, Stephen E., Central, SC, United States Fraser, Scott, La Canada, CA, United States Irvine, Bruce D., Glendora, CA, United States Meade, Thomas J., Altadena, CA, United States O'Connor, Stephen D., Pasadena, CA, United States Terbrueggen, Robert H., Manhattan Beach, CA, United States Vielmetter, Jost G., Pasadena, CA, United States Welch, Thomas W., Pasadena, CA, United States PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation) US 6264825 PI20010724 B1 US 1999-338726 19990623 (9) AΙ RLIContinuation of Ser. No. US 1998-134058, filed on 14 Aug 1998 US 1998-90389P PRAI 19980623 (60) DT Utility FS GRANTED Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex EXNAM Flehr Hohabch Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., LREP Silva, Esq., Robin M. Number of Claims: 29 CLMN Exemplary Claim: 1 DRWN 49 Drawing Figure(s); 22 Drawing Page(s) LN.CNT 5644

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ΑB The invention relates to compositions and methods useful in the acceleration of binding of target analytes to capture ligands on surfaces. Detection proceeds through the use of an electron transfer moiety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM. ANSWER 7 OF 9 USPATFULL on STN L19 2000:142401 USPATFULL Methods of treatment for viral infections IN Camden, James Berger, West Chester, OH, United States The Procter & Gamble Company, Cincinnati, OH, United States (U.S. PΑ corporation) PΙ US 6136835 20001024 ΑI US 1999-394382 19990910 (9) Continuation-in-part of Ser. No. US 1999-312948, filed on 17 May 1999 RLI DТ Utility Granted Primary Examiner: Goldberg, Jerome D. EXNAM LREP Rose and Dabek, Rasser, Jacobus C. Number of Claims: 6 CLMN ECL Exemplary Claim: 1 DRWN No Drawings LN.CNT 1135 CAS INDEXING IS AVAILABLE FOR THIS PATENT. Methods for the treatment of cancers or tumors in mammals are disclosed which uses 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2ol or derivatives thereof. A chemotherapeutic agent and/or a potentiator may be used in combination with 2-(2,4-difluorophenyl)-1,3bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof. 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof may also be used to treat viral infections, either alone, in combination with other anti-viral agents, or in combination with a potentiator. L19 ANSWER 8 OF 9 USPATFULL on STN 1998:161989 USPATFULL TIBiologically compatible linear block copolymers of polyalkylene oxide and **peptide** units Cooper, Eugene R., Berwyn, PA, United States Jones, Stephen P., Morpeth, United Kingdom TN Pouton, Colin W., Bristol, United Kingdom Threadgill, Michael D., Bath, United Kingdom Sterling Winthrop Inc., New York, NY, United States (U.S. corporation) PΑ US 5853713 19981229 PТ ΑĮ US 1997-790854 19970203 (8) Division of Ser. No. US 1994-203106, filed on 28 Feb 1994, now patented, RLI Pat. No. US 5618528 DTUtility FS Granted Primary Examiner: Webman, Edward J. EXNAM Fish & Richardson P.C. LREP Number of Claims: 12 CLMN Exemplary Claim: 1 DRWN No Drawings LN.CNT 1571 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R) -- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs. L19 ANSWER 9 OF 9 USPATFULL on STN 97:29194 USPATFULL ΝA

Biologically compatible linear block copolymers of polyalkylene oxide

TI

```
and peptide units
       Cooper, Eugene R., Berwyn, PA, United States
IN
       Jones, Stephen P., Morpeth, United Kingdom
       Pouton, Colin W., Bristol, United Kingdom
       Threadgill, Michael D., Bath, United Kingdom
       Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PA
ΡI
       US 5618528
                               19970408
       US 1994-203106
                               19940228 (8)
AΙ
DT
       Utility
FS
       Granted
EXNAM Primary Examiner: Webman, Edward J.
LREP
       Fish & Richardson PC
CLMN
       Number of Claims: 17
ECL
       Exemplary Claim: 1
       No Drawings
DRWN
LN.CNT 1632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A linear block copolymer comprising units of an alkylene oxide, linked
AB
       to units of peptide via a linking group comprising a
       --CH.sub.2 CHOHCH.sub.2 N(R) -- moiety, is useful as an imaging agent,
       drug, prodrug or as a delivery system for imaging agents, drugs
       or prodrugs.
=> s 112 and 19 or 113 or 118 or 119
            21 L12 AND L9 OR L13 OR L18 OR L19
=> s Zuo William/au
T<sub>2</sub>21
             0 ZUO WILLIAM/AU
=> s Zuo, W?/au
          289 ZUO, W?/AU
L22
=> s Yu, D?/au
         6679 YU, D?/AU
L23
=> s Yang, D?/au
         10664 YANG, D?/AU
L24
=> s Xu Jing, Y?/au
            37 XU JING, Y?/AU
=> s 120 and 122 or 123 or 124 or 125
        17277 L20 AND L22 OR L23 OR L24 OR L25
=> s 126 and (polypeptide metal complex)
             3 L26 AND (POLYPEPTIDE METAL COMPLEX)
=> d 127 1-3 bib ab
L27 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN
    2003:173371 CAPLUS
     138:226718
DN
    Compositions containing anticancer polypeptide-metal
TI
IN
     Zuo, William W.; Xu, Jing Ya
     Fannin Bioscience, Inc., USA
PΑ
     PCT Int. Appl., 78 pp.
SO
    CODEN: PIXXD2
DТ
    Patent
    English
LA
FAN.CNT 1
    PATENT NO.
                     KIND DATE
                                          APPLICATION NO. DATE
     _____
                     ----
                                          _____
```

WO 2002-US21624 20020709

A2

20030306

рT

WO 2003017923

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
                                             US 2001-940180
     US 2003109432
                        Al
                             20030612
                                                                20011210
PRAI US 2001-940180
                        Α
                             20011210
     Novel drug complexes comprising a polypeptide
     carrier moiety comprising glutamic acid and at
     least one of the group consisting of aspartic acid,
     alanine, asparagine, glutamine,
     glycine, and any combinations thereof, are disclosed.
     The drug moiety is a therapeutic metal
     selected from the group consisting of platinum, iron,
     gadolinium, rhenium, manganese, cobalt,
     indium, gallium or rhodium. Methods for
     making the complexes, compns. comprising the complexes, methods for making
     such compns., and methods for treating a patient with these complexes are
     also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate.
     Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated
     with the poly(amino acid) prepd. above to give a complex.
                                                                   This complex
     was evaluated in 4 tumor-bearing animal models. The platinum
     peptide complexes are all effective in vivo against breast cancer.
     ANSWER 2 OF 3 USPATFULL on STN
L27
AN
       2003:159817 USPATFULL
TI
       Anticancer polypeptide-metal complexes and
       compositions, methods of making, and methods of using same
IN
       Zuo, William W., Sugar Land, TX, UNITED STATES
         Yu, Dongfang, Houston, TX, UNITED STATES
         Yang, David J., Sugar Land, TX, UNITED STATES
         Xu, Jing Ya, Missouri City, TX, UNITED STATES
       US 2003109432
                           A1
                                 20030612
PΙ
       US 2001-940180
                           Α1
                                 20011210 (9)
ΑТ
DT
       Utility
FS
       APPLICATION
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
LREP
       Bellaire, TX, 77402-2428
       Number of Claims: 54
CLMN
ECL
       Exemplary Claim: 1
DRWN
       10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel drug complexes comprising a polypeptide
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
        , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
       The drug moiety is a therapeutic metal
       selected from the group consisting of platinum, iron
        , gadolinium, rhenium, manganese, cobalt,
       indium, gallium or rhodium. Methods for
       making said complexes, compositions comprising said complexes, methods
       for making saiduch compositions, and methods for treating a patient
       comprising use of said complexes and/or compositions are further
       disclosed.
     ANSWER 3 OF 3 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
     2003-363003 [34]
                         WPIDS
AN
DNC
     C2003-095754
```

```
Glutamic acid containing polypeptide-
TI
     metal complexes, useful for treating patients afflicted
     with conditions e.g. cancer.
DC.
     B04 B05
     XU, J Y; YANG, D J; YU, D; ZUO, W W (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W;
IN
PA
     (FANN-N) FANNIN BIOSCIENCE INC
CYC
     97
     WO 2003017923 A2 20030306 (200334)* EN
                                                78p
ΡI
        RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU
            MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
            DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
            KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU
            SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
     US 2003109432 A1 20030612 (200340)
    WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180
ADT
     20010827
PRAI US 2001-940180
                       20010827
     WO2003017923 A UPAB: 20030529
     NOVELTY - A therapeutic compound comprises at least one drug
     moiety covalently linked to at least one
     polypeptide drug carrier moiety (comprising 50
     to 90% glutamic acid and 10 to 50% of aspartic
     acid, alanine, asparagine, glutamine
     and/or glycine).
          DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
           (1) a method for making the therapeutic compound;
           (2) compositions comprising the therapeutic compound;
           (3) a method for making the composition;
           (4) a method for treating a patient comprising administration of the
     compound.
          ACTIVITY - Cytostatic.
          Cis-1,2-diaminocyclohexane platinum(II
     )-poly(glutamic/aspartic acid) (Ia) at 45 mg/kg
     reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control
     treated with saline showed tumor growth over 6 days to 16000 mm3.
          MECHANISM OF ACTION - None given.
     USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic,
     leukemia, lymphoma, sarcoma, head and neck, lung or liver).
          ADVANTAGE - The compounds have improved solubility of the therapeutic
     agent.
     Dwg.0/7
=> d his
     (FILE 'HOME' ENTERED AT 16:01:55 ON 26 SEP 2003)
     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
     ENTERED AT 16:02:05 ON 26 SEP 2003
        1697755 S (POLYPEPTIDE# OR PEPTIDE# OR THERAPEUT? PEPTIDE OR POLYPEPTID
L1
         166239 S L1 AND (GLUTAMIC ACID OR ASPARTIC ACID OR ALANINE OR ASPARAGI
L2
L3
               0 S L2 AND (DRUG CARIIER)
               0 S L2 AND (DRUG CARIER)
Ъ4
          39614 S L2 AND (CARRIER)
L5
1.6
          24549 S L5 AND (DRUG)
           2071 S L6 AND (METAL COMPLEX?)
L7
           2070 S L7 AND (CONJUGAT? OR COMBIN? OR JOIN? OR LINK? (5A) COVALENT?
L8
L9
               7 S L8 AND (METAL DRUG)
              1 S L8 AND (TRANSITION? METAL DRUG)
L10
           2070 S L8 AND (METAL COMPLEX?)
L11
            647 S L11 AND (PLATINUM OR IRON OR GADOLINIUM OR RHENIUM OR MANGANE
L12
               8 S L12 AND (THERAPEUTIC METAL)
L13
```

```
O S L12 AND (POLYPEPTIDE PLATNIUM COMPLEX)
L15
              0 S L12 AND (PLATNIUM COMPLEX?)
              0 S L12 AND (PLATNIUM)
L16
              0 S L12 AND (POLYGLUTAMATE ASPARATATE OR POLYGLUTAMATE ALANINE)
L17
              2 S L12 AND (DIAMINOCYCLOHEXANE PLATINUM II OR DIAMINOCYCLOHEXANE
L18
              9 S L12 AND (PLATINUM COMPLEX?)
L19
             21 S L12 AND L9 OR L13 OR L18 OR L19
L20
L21
              0 S ZUO WILLIAM/AU
            289 S ZUO, W?/AU
L22
           6679 S YU, D?/AU
L23
L24
          10664 S YANG, D?/AU
             37 S XU JING, Y?/AU
L25
          17277 S L20 AND L22 OR L23 OR L24 OR L25
L26
              3 S L26 AND (POLYPEPTIDE METAL COMPLEX)
=> d 120 1-21 bib ab
L20 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
     2003:173371 CAPLUS
DN
     138:226718
     Compositions containing anticancer polypeptide-metal
TI
     complexes
TN
     Zuo, William W.; Xu, Jing Ya
     Fannin Bioscience, Inc., USA
PA
     PCT Int. Appl., 78 pp.
SO
     CODEN: PIXXD2
     Patent
DT
     English
FAN.CNT 1
                      KIND DATE
                                             APPLICATION NO. DATE
     PATENT NO.
     ______
                             _____
                                             _____
     WO 2003017923 A2 20030306
                                       WO 2002-US21624 20020709
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             US 2001-940180
                             20030612
                                                               20011210
     US 2003109432
                      A1
                      Α
                            20011210
PRAI US 2001-940180
     Novel drug complexes comprising a polypeptide
     carrier moiety comprising glutamic acid and at
     least one of the group consisting of aspartic acid,
     alanine, asparagine, glutamine,
     glycine, and any combinations thereof, are disclosed.
     The drug moiety is a therapeutic metal
     selected from the group consisting of platinum, iron,
     gadolinium, rhenium, manganese, cobalt,
     indium, gallium or rhodium. Methods for
     making the complexes, compns. comprising the complexes, methods for making
     such compns., and methods for treating a patient with these complexes are
     also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by
     the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate.
     Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated
     with the poly(amino acid) prepd. above to give a complex.
                                                                   This complex
     was evaluated in 4 tumor-bearing animal models. The platinum
     peptide complexes are all effective in vivo against breast cancer.
L20 ANSWER 2 OF 21 USPATFULL on STN
       2003:203373 USPATFULL
AN
       Electronic methods for the detection of analytes utilizing monolayers
```

Yu, Changjun, Pasadena, CA, United States

TI

IN

```
Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S.
PA
       corporation)
      US 6600026
                               20030729
                          B1
PΙ
                               19990506 (9)
ΑI
       US 1999-306653
       Continuation of Ser. No. US 1998-135183, filed on 17 Aug 1998
RLI
                           19980506 (60)
PRAI
       US 1998-84652P
       US 1998-84509P
                           19980506 (60)
DТ
       Utility
       GRANTED
      Primary Examiner: Riley, Jezia
       Silva, Robin M., Kosslak, Renee M., Dorsey & Whitney, LLP
LREP
       Number of Claims: 12
CLMN
ECL
       Exemplary Claim: 1
DRWN
       93 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 4573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The present invention relates to the use of self-assembled monolayers
AB
       with mixtures of conductive oligomers and insulators to detect target
       analytes.
    ANSWER 3 OF 21 USPATFULL on STN
L20
       2003:176406 USPATFULL
AN
       Pharmaceutical preparations of glutathione and methods of administration
TI
       thereof
       Demopolos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Pleasantville, NY, United States
       Antioxidant Pharmaceuticals Corp., Elsmsford, NY, United States (U.S.
PΑ
       corporation)
                               20030701
PT
       US 6586404
                          B1
       US 2002-200852
                               20020722 (10)
AΙ
RLI
       Continuation of Ser. No. US 2001-813247, filed on 19 Mar 2001, now
       patented, Pat. No. US 6423687 Continuation of Ser. No. US 1997-2100,
       filed on 31 Dec 1997, now patented, Pat. No. US 6159500 Continuation of
       Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US
       6204248
                           19961231 (60)
PRAI
       US 1996-34101P
       Utility
DT
       GRANTED
      Primary Examiner: Reamer, James H.
EXNAM
       Milde & Hoffberg LLP
LREP
       Number of Claims: 33
CLMN
       Exemplary Claim: 1,20
       2 Drawing Figure(s); 2 Drawing Page(s)
DRWN
LN.CNT 3836
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method for the administration of glutathione orally comprising the
       administration of a bolus of glutathione which is pharmaceutically
       stabilized and encapsulated. The glutathione is administered on an empty
       stomach. The preferred stabilizer is ascorbic acid.
    ANSWER 4 OF 21 USPATFULL on STN
       2003:159817 USPATFULL
AN
       Anticancer polypeptide-metal complexes and
TТ
       compositions, methods of making, and methods of using same
       Zuo, William W., Sugar Land, TX, UNITED STATES
IN
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES
       Xu, Jing Ya, Missouri City, TX, UNITED STATES
ΡI
       US 2003109432
                          Α1
                               20030612
       US 2001-940180
                          A1
                               20011210 (9)
ΑI
       Utility
DT
FS
       APPLICATION
       J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
LREP
       Bellaire, TX, 77402-2428
       Number of Claims: 54
CLMN
```

```
Exemplary Claim: 1
DRWN
       10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel drug complexes comprising a polypeptide
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
       , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
       The drug moiety is a therapeutic metal
       selected from the group consisting of platinum, iron
       , gadolinium, rhenium, manganese, cobalt,
       indium, gallium or rhodium. Methods for
       making said complexes, compositions comprising said complexes, methods
       for making saiduch compositions, and methods for treating a patient
       comprising use of said complexes and/or compositions are further
       disclosed.
L20 ANSWER 5 OF 21 USPATFULL on STN
       2002:322479 USPATFULL
AN
       Methods of high-throughput screening for internalizing antibodies
TI
       Marks, James D., Kensington, CA, UNITED STATES
TN
       Nielsen, Ulrik B., Brookline, MA, UNITED STATES
       Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
       US 2002182643
                               20021205
PΙ
                          A1
       US 2001-981636
                          A1
                               20011016 (9)
AΙ
                           20001018 (60)
PRAI
       US 2000-241279P
       Utility
DT
FS
       APPLICATION
       QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
LREP
       94501
CLMN
       Number of Claims: 72
ECL
       Exemplary Claim: 1
       8 Drawing Page(s)
DRWN
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       This invention provides methods of identifying ligands that are
       internalized into a cell. The methods typically involve i) contacting
       the cell with a reporter non-covalently coupled to a ligand; ii)
       dissociating the reporter from the ligand and removing dissociated
       reporter from the surface of the cell; and iii) detecting the reporter
       within said cell (if any is present) where the presence of the reporter
       within said cell indicates that the ligand binds to an internalizing
       receptor and is internalized.
    ANSWER 6 OF 21 USPATFULL on STN
L20
AN
       2002:250825 USPATFULL
       Pharmaceutical preparations of glutathione and methods of administration
TI
IN
       Demopoulos, Harry B., Scarsdale, NY, UNITED STATES
       Seligman, Myron L., Pleasantville, NY, UNITED STATES
PT
       US 2002136763
                          A1
                               20020926
                               20020225 (10)
ΑТ
       US 2002-83327
                          A1
       A 371 of International Ser. No. WO 1997-US23879, filed on 31 Dec 1997,
RLI
       UNKNOWN Continuation-in-part of Ser. No. US 1999-331947, filed on 28 Jun
       1999, GRANTED, Pat. No. US 6350467
PRAI
       US 1996-34101P
                           19961231 (60)
DT
       Utility
FS
       APPLICATION
       Steven M. Hoffberg, MILDE & HOFFBERG, LLP, SUITE 460, 10 BANK STREET,
LREP
       WHITE PLAINS, NY, 10606
CLMN
       Number of Claims: 59
       Exemplary Claim: 1
DRWN
       2 Drawing Page(s)
LN.CNT 2416
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT. A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed. L20 ANSWER 7 OF 21 USPATFULL on STN 2002:181670 USPATFULL ANPharmaceutical preparations of glutathione and methods of administration TI Demopolos, Harry B., Scarsdale, NY, United States TM Seligman, Myron L., Pleasantville, NY, United States PΑ Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation) 20020723 US 6423687 B1. PT US 2001-813247 20010319 (9) AΙ Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now RLI patented, Pat. No. US 6204248 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now patented, Pat. No. US 6159500 US 1996-34101P 19961231 (60) PRAI Utility DT FSGRANTED Primary Examiner: Reamer, James H. EXNAMMilde & Hoffberg, LLP LREP Number of Claims: 20 CLMN ECL Exemplary Claim: 1 2 Drawing Figure(s); 2 Drawing Page(s) LN.CNT 3706 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid. ANSWER 8 OF 21 USPATFULL on STN L202002:39674 USPATFULL ANPharmaceutical preparations of glutathione and methods of administration TIthereof Demopoulos, Harry B., Scarsdale, NY, United States TN Seligman, Myron L., Pleasantville, NY, United States Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. PAcorporation) US 6350467 B1. 20020226 PΤ WO 9829101 19980709 US 1999-331947 19990628 (9) AΙ WO 1997-US23879 19971231 19990628 PCT 371 date US 1996-34101P 19961231 (60) PRAI DT Utility FS GRANTED Primary Examiner: Spear, James M. EXNAM Milde, Hoffberg & Macklin, LLP LREP Number of Claims: 62 CLMN Exemplary Claim: 1 2 Drawing Figure(s); 2 Drawing Page(s) LN.CNT 2366 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

2001:231038 USPATFULL ΑN TI Structurally determined cyclic metallo-constructs and applications Sharma, Shubh D., Plainsboro, NJ, United States IN Palatin Technologies, Inc., Princeton, NJ, United States (U.S. PΑ corporation) US 6331285 В1 20011218 PI US 1999-464358 19991215 (9) ΑI Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, RLI Pat. No. US 6027711 Utility DT FS GRANTED Primary Examiner: Jones, Dameron L. EXNAM Slusher, Stephen A.Peacock, Myers & Adams LREP CLMN Number of Claims: 16 ECL Exemplary Claim: 1 20 Drawing Figure(s); 14 Drawing Page(s) DRWN LN.CNT 4839 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula: R.sub.1 --X--R.sub.2 where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion. L20 ANSWER 10 OF 21 USPATFULL on STN 2001:157679 USPATFULL ANSystems for electrophoretic transport and detection of analytes TI Kayyem, Jon Faiz, Pasadena, CA, United States TN Blackburn, Gary, Glendora, CA, United States O'Connor, Stephen D., Pasadena, CA, United States Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. PA corporation) PΙ US 6290839 B120010918 19980814 (9) US 1998-134058 ΑI US 1998-90389P 19980623 (60) PRAI Utility DT GRANTED Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex EXNAM Flehr Hohbach Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., Silva, Esq., Robin M. Number of Claims: 28 CLMN Exemplary Claim: 1 ECL 44 Drawing Figure(s); 21 Drawing Page(s) DRWN LN.CNT 4594 CAS INDEXING IS AVAILABLE FOR THIS PATENT. The invention relates to compositions and methods useful in the electrophoretic transport of target analytes to a detection electrode

comprising a self-assembled monolayer (SAM). Detection proceeds through

the use of an electron transfer moiety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM.

```
L20
    ANSWER 11 OF 21 USPATFULL on STN
       2001:116434 USPATFULL
AN
       Binding acceleration techniques for the detection of analytes
TI
IN
       Blackburn, Gary, Glendora, CA, United States
       Creager, Stephen E., Central, SC, United States
       Fraser, Scott, La Canada, CA, United States
       Irvine, Bruce D., Glendora, CA, United States
       Meade, Thomas J., Altadena, CA, United States
       O'Connor, Stephen D., Pasadena, CA, United States
       Terbrueggen, Robert H., Manhattan Beach, CA, United States
       Vielmetter, Jost G., Pasadena, CA, United States
       Welch, Thomas W., Pasadena, CA, United States
       Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S.
PA
       corporation)
       US 6264825
                          В1
                               20010724
PΙ
       US 1999-338726
                               19990623 (9)
AI
       Continuation of Ser. No. US 1998-134058, filed on 14 Aug 1998
RLI
PRAI
       US 1998-90389P
                           19980623 (60)
DT
       Utility
       GRANTED
FS
       Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex
EXNAM
       Flehr Hohabch Test Albritton & Herbert LLP, Trecartin, Esq., Richard F.,
LREP
       Silva, Esq., Robin M.
       Number of Claims: 29
CLMN
ECL
       Exemplary Claim: 1
       49 Drawing Figure(s); 22 Drawing Page(s)
DRWN
LN.CNT 5644
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The invention relates to compositions and methods useful in the
AB
       acceleration of binding of target analytes to capture ligands on
       surfaces. Detection proceeds through the use of an electron transfer
       moiety (ETM) that is associated with the target analyte, either directly
       or indirectly, to allow electronic detection of the ETM.
    ANSWER 12 OF 21 USPATFULL on STN
L20
       2001:40462 USPATFULL
AN
       Pharmaceutical preparations of glutathione and methods of administration
TI
       Demopoulos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Fairfield, CT, United States
       Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
PΑ
       corporation)
                               20010320
PΙ
       US 6204248
                          B1
                               19991209 (9)
       US 1999-457642
ΑI
       Continuation of Ser. No. US 331947 Continuation of Ser. No. US
RIT
       1997-2100, filed on 31 Dec 1997, now abandoned
PRAI
       US 1996-34101P
                           19961231 (60)
DT
       Utility
FS
       Granted
      Primary Examiner: Reamer, James H.
EXNAM
LREP
       Milde, Hoffberg & Macklin, LLP
CLMN
       Number of Claims: 14
       Exemplary Claim: 1
ECL
DRWN
       2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 5144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method of altering an expression of a gene product in cells or an
AΒ
       organism, comprising orally administering glutathione in an effective
       amount and under such conditions to alter a redox potential in the
       cells. The gene expression may be sensitive to redox potential through
       one or more of a process of induction, transcription, translation,
```

post-translational modification, release, and/or through a receptor mediated process. The glutathione is preferably administered as an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach.

```
ANSWER 13 OF 21 USPATFULL on STN
       2000:167548 USPATFULL
ΝA
       Pharmaceutical preparations of glutathione and methods of administration
TΙ
       Demopoulos, Harry B., Scarsdale, NY, United States
IN
       Seligman, Myron L., Pleasantville, NY, United States
       Antioxidant Pharmaceuticals Corporation, Elmsford, NY, United States
PΑ
       (U.S. corporation)
PΙ
       US 6159500
                               20001212
       US 1997-2100
                               19971231 (9)
ΑI
DT
       Utility
FS
       Granted
       Primary Examiner: Spear, James M.
EXNAM
       Milde, Hoffberg & Macklin, LLP
CLMN
       Number of Claims: 59
ECL
       Exemplary Claim: 1
DRWN
       2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method for the administration of glutathione orally comprising the
       administration of a bolus of glutathione which is pharmaceutically
       stabilized and encapsulated. The glutathione is administered on an empty
       stomach. The preferred stabilizer is ascorbic acid.
    ANSWER 14 OF 21 USPATFULL on STN
L20
AN
       2000:142401 USPATFULL
TI
       Methods of treatment for viral infections
       Camden, James Berger, West Chester, OH, United States
IN
       The Procter & Gamble Company, Cincinnati, OH, United States (U.S.
PΑ
       corporation)
       US 6136835
                               20001024
PΙ
       US 1999-394382
                               19990910 (9)
AI
       Continuation-in-part of Ser. No. US 1999-312948, filed on 17 May 1999
RLI
       Utility
DT
FS
       Granted
       Primary Examiner: Goldberg, Jerome D.
EXNAM
       Rose and Dabek, Rasser, Jacobus C.
LREP
       Number of Claims: 6
CLMN
ECT.
       Exemplary Claim: 1
       No Drawings
LN.CNT 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Methods for the treatment of cancers or tumors in mammals are disclosed
       which uses 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-
       ol or derivatives thereof. A chemotherapeutic agent and/or a potentiator
       may be used in combination with 2-(2,4-difluorophenyl)-1,3-
       bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof.
       2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or
       derivatives thereof may also be used to treat viral infections, either
       alone, in combination with other anti-viral agents, or in
       combination with a potentiator.
L20 ANSWER 15 OF 21 USPATFULL on STN
       2000:109372 USPATFULL
AN
TT
       In vivo agents comprising cationic drugs, peptides and metal
       chelators with acidic saccharides and glycosaminoglycans, giving
       improved site-selective localization, uptake mechanism, sensitivity and
       kinetic-spatial profiles, including tumor sites
IN
       Ranney, David F., Dallas, TX, United States
DΔ
       Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S.
```

corporation) PI US 6106866 20000822 US 1995-509338 19950731 (8) AΙ DT Utility FS Granted Primary Examiner: Woodward, Michael P. EXNAM Arnold, White & Durkee LREP Number of Claims: 23 CLMN Exemplary Claim: 1 21 Drawing Figure(s); 72 Drawing Page(s) DRWN LN.CNT 3913 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A drug carrier composition comprising a drug complexed with dermatan sulfate is disclosed. The drug is preferably an anti tumor drug and may be taxol, a peptide onco-agent or vincristine. The most preferred antitumor drug is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9% (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induces the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; 3) acceleration of the carrier's transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (interstitium); and 4) improvement of the efficiency with which the drug migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel. ANSWER 16 OF 21 USPATFULL on STN AN2000:21206 USPATFULL Structurally determined metallo-constructs and applications TΤ INSharma, Shubh D., Albuquerque, NM, United States PA RhoMed Incorporated, Edison, NJ, United States (U.S. corporation) PIUS 6027711 20000222 US 1996-660697 19960605 (8) AΙ Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, RLT now patented, Pat. No. US 5891418, issued on 6 Apr 1999 DT Utility Granted FS EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Jones, Dameron Slusher, Stephen A., Todaro, John C., Peacock, Deborah A. LREP CLMN Number of Claims: 38 ECLExemplary Claim: 1 20 Drawing Figure(s); 14 Drawing Page(s) DRWN LN.CNT 4915 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula: R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X,

resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

```
L20 ANSWER 17 OF 21 USPATFULL on STN
AN
       1998:161989 USPATFULL
       Biologically compatible linear block copolymers of polyalkylene oxide
ΤI
       and peptide units
       Cooper, Eugene R., Berwyn, PA, United States
TN
       Jones, Stephen P., Morpeth, United Kingdom
       Pouton, Colin W., Bristol, United Kingdom
       Threadgill, Michael D., Bath, United Kingdom
       Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PA
PΙ
       US 5853713
                               19981229
ΑI
       US 1997-790854
                               19970203 (8)
RLI
       Division of Ser. No. US 1994-203106, filed on 28 Feb 1994, now patented,
       Pat. No. US 5618528
       Utility
DT
FS
       Granted
      Primary Examiner: Webman, Edward J.
EXNAM
       Fish & Richardson P.C.
CLMN
       Number of Claims: 12
       Exemplary Claim: 1
ECL
DRWN
       No Drawings
LN.CNT 1571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A linear block copolymer comprising units of an alkylene oxide, linked
AB
       to units of peptide via a linking group comprising a
       --CH.sub.2 CHOHCH.sub.2 N(R) -- moiety, is useful as an imaging agent,
       drug, prodrug or as a delivery system for imaging agents, drugs
       or prodrugs.
    ANSWER 18 OF 21 USPATFULL on STN
L20
       1998:138472 USPATFULL
AN
       Dendrimeric compounds
TI
       Margerum, Larry, Wayne, PA, United States
IN
       Campion, Brian, Solano Beach, CA, United States
       Fellmann, Jere Douglas, Livermore, CA, United States
       Garrity, Martha, San Clemente, CA, United States
       Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
PΑ
PΙ
       US 5834020
                               19981110
       WO 9528966
                  19951102
ΑI
       US 1997-722082
                               19970121 (8)
       WO 1995-GB898
                               19950420
                               19970121 PCT 371 date
                               19970121 PCT 102(e) date
       GB 1994-7812
                           19940420
PRAI
       Utility
       Granted
FS
      Primary Examiner: Levy, Neil S.
EXNAM
LREP
       Fish & Richardson P.C.
       Number of Claims: 17
CLMN
       Exemplary Claim: 1
ECL
       No Drawings
DRWN
LN.CNT 2049
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The invention provides a dendrimeric compound comprising a dendrimeric
AΒ
       bioactive moiety with linked thereto a plurality of diagnostically or
```

3

therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

```
ANSWER 19 OF 21 USPATFULL on STN
       97:29194 USPATFULL
MA
       Biologically compatible linear block copolymers of polyalkylene oxide
TI
       and peptide units
IN
       Cooper, Eugene R., Berwyn, PA, United States
       Jones, Stephen P., Morpeth, United Kingdom
       Pouton, Colin W., Bristol, United Kingdom
       Threadgill, Michael D., Bath, United Kingdom
Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PA
                                19970408
PI
       US 5618528
       US 1994-203106
                                19940228 (8)
ΑI
DT
       Utility
       Granted
EXNAM
       Primary Examiner: Webman, Edward J.
LREP
       Fish & Richardson PC
       Number of Claims: 17
CLMN
ECL
       Exemplary Claim: 1
DRWN
       No Drawings
LN.CNT 1632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A linear block copolymer comprising units of an alkylene oxide, linked
AΒ
       to units of peptide via a linking group comprising a
       --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent,
       drug, prodrug or as a delivery system for imaging agents, drugs
       or prodrugs.
L20 ANSWER 20 OF 21 USPATFULL on STN
       93:93543 USPATFULL
AN
       Methods and compositions for magnetic resonance imaging comprising
ΤТ
       superparamagnetic ferromagnetically coupled chromium complexes
IN
       Ranney, David F., 3539 Courtdale Dr., Dallas, TX, United States 75234
PΙ
       US 5260050
                                19931109
       US 1990-463692
ΑI
                                19900111 (7)
DCD
       20100525
RLI
       Continuation-in-part of Ser. No. US 1988-252565, filed on 29 Sep 1988,
       now abandoned
DT
       Utility
FS
       Granted
       Primary Examiner: Hollrah, Glennon H.; Assistant Examiner: Hollinden,
EXNAM
       Gary E.
LREP
       Arnold, White Durkee
       Number of Claims: 29
CLMN
ECL
       Exemplary Claim: 1
DRWN
       8 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB
       Improved compositions and methods for selective access to tumor regions
       (or other regions of abnormal endothelial properties). This capability
       provides powerful contrast-enhancement agents for nuclear magnetic
       resonance imaging. A polyatomic complex which includes intramolecular
       ferromagnetic coupling between metal atoms is associated with a polymer
       or microsphere carrier matrix which will bind to endothelial
       determinants. A solution containing this carrier complex is
       injected into a human (or other) body to be imaged. The carrier
       complex will preferentially extravasate at locations where the blood
       vessel walls have increased porosity or microvascular surface changes,
       and especially at tumor sites. Thus, the changes in relaxation time
       induced by the presence of the carrier complex will provide a
       high-gain marker for magnetic resonance imaging.
```

Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core. ANSWER 21 OF 21 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN 2003-363003 [34] WPTDS DNC C2003-095754 Glutamic acid containing polypeptidemetal complexes, useful for treating patients afflicted with conditions e.g. cancer. XU, JY; YANG, DJ; YU, D; ZUO, WW (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; (FANN-N) FANNIN BIOSCIENCE INC CYC 97 WO 2003017923 A2 20030306 (200334)* EN 78p RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW US 2003109432 A1 20030612 (200340) WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 ADT20010827 20010827 PRAI US 2001-940180 WO2003017923 A UPAB: 20030529 NOVELTY - A therapeutic compound comprises at least one drug moiety covalently linked to at least one polypeptide drug carrier moiety (comprising 50 to 90% glutamic acid and 10 to 50% of aspartic acid, alanine, asparagine, glutamine and/or glycine). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a method for making the therapeutic compound; (2) compositions comprising the therapeutic compound; (3) a method for making the composition; (4) a method for treating a patient comprising administration of the compound. ACTIVITY - Cytostatic. Cis-1, 2-diaminocyclohexane platinum(II)-poly(glutamic/aspartic acid) (Ia) at 45 mg/kg reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control treated with saline showed tumor growth over 6 days to 16000 mm3. MECHANISM OF ACTION - None given. USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic, leukemia, lymphoma, sarcoma, head and neck, lung or liver). ADVANTAGE - The compounds have improved solubility of the therapeutic agent. Dwg.0/7 ---Logging off of STN---

=> LOG Y

Executing the logoff script...

=>

AN

DC: IN

PΑ

PΤ

STN INTERNATIONAL LOGOFF AT 16:39:50 ON 26 SEP 2003